All In Biotech

Drug Trial Radar · NCT06701305

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen

Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jun 13, 2024

Primary completion

Feb 18, 2025

Study completion Feb 18, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it. Researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (Part 1) or as multiple doses (Part 2). In addition, the study will assess the amount of acetaminophen in the blood after receiving different strength doses of efinopegdutide (Part 2 only).

Conditions

  • Healthy

Interventions

  • EfinopegdutideDrug

    Subcutaneous injectable solution

  • PlaceboDrug

    Subcutaneous injectable solution

  • AcetaminophenDrug

    Oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 35 days
  2. Part 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 35 days
  3. Part 1: Maximum Plasma Concentration (Cmax) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
  4. Part 1: Time to Maximum Plasma Concentration (Tmax) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
  5. Part 1: Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration (AUC0-last) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
  6. Part 1: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
  7. Part 1: Apparent Terminal Half-life (t1/2) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
  8. Part 1: Apparent Clearance (CL/F) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
  9. Part 1: Apparent volume of distribution during terminal phase (Vz/F) of EfinopegdutideTime frame: Pre-dose and at designated time points up to 35 days post dose
  10. Part 2: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 184 days
  11. Part 2: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 184 days
  12. Part 2: Cmax of EfinopegdutideTime frame: At designated time points up to approximately 184 days
  13. Part 2: Tmax of EfinopegdutideTime frame: At designated time points up to approximately 184 days
  14. Part 2: Area Under the Concentration-Time Curve from Time 0 to the End of the Dosing Interval (AUC0-tau) of EfinopegdutideTime frame: At designated time points up to approximately 184 days
  15. Part 2: t1/2 of EfinopegdutideTime frame: At designated time points up to approximately 184 days
  16. Part 2: Vz/F of EfinopegdutideTime frame: At designated time points up to approximately 184 days
  17. Part 2: Concentration Immediately Before the Next Dose is Administered (Ctrough) of EfinopegdutideTime frame: At designated time points up to approximately 184 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QPS-MRA, LLC (Site 0001)

    South Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.